GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GlaxoSmithKline is under pressure from shareholders ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

Shares of GSK PLC GSK dropped 1.59% to £13.92 Tuesday ... Supported by world-class markets data from Dow Jones and FactSet, ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily ...

It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...

By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

BRENTFORD, Britain — BRENTFORD, Britain — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of 4 cents per share ...

GlaxoSmithKline is under pressure from shareholders ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.